Theralase Technologies has the GF Score of 39, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Theralase Technologies
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Theralase Technologies GF Score Related Terms
TSXV:TLT vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, Theralase Technologies's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's GF Score distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's GF Score falls into.
Theralase Technologies (TSXV:TLT) has a GF Score of 39 as of Jul. 06, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Theralase Technologies and its competitors. This is near median its historical median of 42.00. Over the past decade, Theralase Technologies' GF Score has ranged from 28.00 to 55.00.
Is Theralase Technologies' GF Score too high?
Theralase Technologies' current GF Score of 39 is near median its 10-year median of 42.00. Over the past 10 years, this metric has ranged from a low of 28.00 to a high of 55.00. Overall, Theralase Technologies has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' GF Score compare to ABT and SYK?
Theralase Technologies' GF Score of 39 can be compared against companies in the Medical Devices & Instruments industry. Historically, Theralase Technologies' own GF Score has ranged from 28.00 to 55.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current GF Score is 39, which is near median its own 10-year median of 42.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TSXV:TLT) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.18, compared to a current price of C$0.26 — trading 44.4% above its estimated fair value. The current GF Score is 39, which is near median its 10-year median of 42.00. Theralase Technologies' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Theralase Technologies (TSXV:TLT), the current GF Score is 39 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TSXV:TLT) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of C$0.26 is trading 44.4% above its estimated GF Value™ of C$0.18.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TSXV:TLT:
GF Score: 39 (near median its 10-year median of 42.00)
GF Value™: C$0.18 vs. price of C$0.26 (44.4% above fair value)
No single metric tells the full story. See the TSXV:TLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
39GF Score
Get the complete analysis for TSXV:TLT
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:TLT has been successfully added to your 